Optimizing the Diagnosis of Parkinsonian Syndromes With I-Ioflupane Brain SPECT.

Authors:
Kevin P Banks
Kevin P Banks
University of Alabama School of Medicine
United States
Justin G Peacock
Justin G Peacock
Department of Graduate Medical Education
Durham | United States
Michael N Clemenshaw
Michael N Clemenshaw
San Antonio Military Medical Center
Phillip H Kuo
Phillip H Kuo
Yale University School of Medicine
United States

AJR Am J Roentgenol 2019 Apr 17:1-11. Epub 2019 Apr 17.

3 Department of Medical Imaging, University of Arizona, Tucson, AZ.

The purpose of this article is to provide a review of I-ioflupane SPECT in the evaluation of suspected parkinsonian syndromes (PSs). This collection of diseases presents frequent diagnostic challenges, even by movement disorder and dementia specialists. The I-ioflupane scan serves as an imaging biomarker of the status of presynaptic dopamine transporters (DATs) in the striatum. As a result of neuronal death, DATs are greatly reduced in patients with PS neurodegenerative disorders, whereas clinical mimics generally do not show striatal DAT loss. This provides a tremendous opportunity for I-ioflupane to aid in the accurate and timely diagnosis of these patients and optimize their management.

Download full-text PDF

Source
https://www.ajronline.org/doi/10.2214/AJR.19.21088
Publisher Site
http://dx.doi.org/10.2214/AJR.19.21088DOI Listing
April 2019
4 Reads

Publication Analysis

Top Keywords

parkinsonian syndromes
8
i-ioflupane scan
4
specialists i-ioflupane
4
dat loss
4
scan serves
4
imaging biomarker
4
serves imaging
4
striatal dat
4
dementia specialists
4
loss tremendous
4
diagnostic challenges
4
opportunity i-ioflupane
4
frequent diagnostic
4
patients neurodegenerative
4
challenges movement
4
generally striatal
4
movement disorder
4
disorder dementia
4
status presynaptic
4
death dats
4

Similar Publications